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I.

INTRODUCTION

On April 12, 1988, the Patent and Trademark Office (PTO) issued
patent No. 4,736,866 for a "transgenic, non-human mammal," a genetically engineered mouse created by scientists at Harvard Medical
School., The "Harvard mouse" patent was the world's first patent for

*Portions of this article were presented January 23, 1988 at the Center for Governmental
Responsibility Conference on New Developments in Biotechnology.
**B.A., 1986; J.D. Candidate, University of Florida. The author is the Senior Articles Editor
of the University of Florida Law Review and will clerk for The Honorable Howell W. Melton,
District Judge, Middle District of Florida, following graduation.
1. Gainesville Sun, Apr. 13, 1988 at Al, All; 35 PAT. TRADEMARK & COPYRIGHT J.
(BNA) 508 (Apr. 14, 1988). Dr. Phillip Leder, geneticist at Harvard Medical College and Dr.
Timothy A. Stewart, former Harvard researcher and scientist at Genentech, Inc., a leading
biotechnology company, developed the "Harvard mouse." Gainesville Sun, Apr. 13, 1988, at Al.
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a higher life form. 2 By altering the genetic structure of the mouse,
scientists made it more susceptible to cancer, 3 thereby creating a valuable tool for cancer research.4
The PTO broke new ground in patenting by issuing a patent for
a multicellular life form.5 Before the "Harvard mouse" patent, the
PTO issued patents primarily for new microorganisms or plants developed with biotechnology.6 Biotechnology is generally defined as the
use of living organisms in a manufacturing or productive role. 7 Genetic
engineering and recombinant DNA (deoxyribonucleic acid) techniques
are most commonly associated with biotechnology."
The biotechnology revolution of the 1980s encouraged investment
in product research and development, spawning numerous advances
in agriculture, food processing, forestry, waste disposal, pollution con-

2. The term higher life form refers to multicellular, complex organisms as distinguished
from unicellular or simple bacteria and other microorganisms.
Commentators describe the "Harvard mouse" patent as a "singularly historic event" and as
an "historic step." Gainesville Sun, Apr. 13, 1988, at Al. The scientists injected a cancer-causing
gene into fertilized mouse eggs to develop the breed of genetically altered mice. 35 PAT.
TRADEMARK & COPYRIGHT J. (BNA) 508 (Apr. 14, 1988).
3. 35 PAT. TRADEMARK & COPYRIGNT J. (BNA) 508 (Apr. 14, 1988).
4. "The patented animals thus serve as valuable 'cancer detectives' in testing cancer-producing chemicals. The chemicals can be tested in amounts comparable to those that a human would
be exposed to in the same environment. The offspring of these animals will also have the same
cancer-detecting feature." Id.
DuPont sponsored the "Harvard mouse" research. The PTO granted DuPont the exclusive
license to use the "Harvard mouse." For other uses of genetically altered animals, see infra
part IV, section A.
5. In Diamond v. Chakrabarty, 447 U.S. 303 (1980), the United States Supreme Court
held for the first time that living organisms are patentable under general patent law. For a
detailed discussion of Chakrabarty, see infra part II, section C.
6. See infra part II, The History of Living Organisms as Patentable Subject Matter.
7. Biotechnology includes techniques that use living organisms to make or modify products,
to improve plants or animals, or to develop microorganisms for specific use. OFFICE OF
TECHNOLOGY
ASSESSMENT,
U.S.
CONG.,
OTA-BA 360, NEW DEVELOPMENTS IN
BIOTECHNOLOGY: U.S. INVESTMENT IN BIOTECHNOLOGY SPECIAL REPORT 3 (1988)
[hereinafter OTA: INVESTMENT]; Note, Microorganisms and the Patent Office: To Deposit or
Not to Deposit, That is the Question, 52 FORDHAM L. REV. 593 n.1 (1984) (authored by John
Edward Schneider).
8. DNA is the double helix molecule that stores genetic information in all living organisms.
DNA codes the genetic information in all living organisms which determines the structure and
function of an organism. OTA: INVESTMENT, supra note 7, at 287. The term recombinant DNA
is often used synonymously with the term genetic engineering but more accurately describes a
DNA molecule constructed by genetic engineering and composed of DNA from different individuals or species. Id. at 288.
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trol, pharmaceuticals, and health care. 9 Patent law protects investments in time-consuming and costly technology research and development by discouraging patent infringement. However, current
biotechnology research has far out-paced patent laws, which are illequipped to embrace the intricate processes and products of modern
biotechnological advances. 1°
This article explores issues and problems raised by the "Harvard
mouse" patent for a higher life form. Part II discusses the history of
living organisms as patentable subject matter, and part III addresses
other legal problems associated with granting patents for living organisms created using biotechnology. Part IV reviews public policy
considerations associated with biotechnology, and part V proposes
revisions of general patent laws to address legal problems and policy
considerations involved in patenting the living products of biotechnology.

II.

HISTORY OF LIVING ORGANISMS AS PATENTABLE
SUBJECT MATTER

A. Living Organisms Not Subject to Patent Protection
"Whoever invents or discovers any new and useful . . . manufacture, or composition of matter, . . . may obtain a patent therefor . . . . "I' Until 1980, when the United States Supreme Court held
that man-made, oil-ingesting bacteria were patentable subject matter
2
in Diamond v. Chakrabarty,1
living organisms did not constitute patentable subject matter under the general patent laws.13 Courts were
unwilling to place living organisms under the definition of patentable
subject matter as either "manufacture(s)" or "composition(s) of matter. 14 Though the use of living organisms in a process had long been

9. For a discussion of the congruence of patent protection for biotechnology inventions and
scientific norms, see Eisenberg, ProprietaryRights and the Norms of Science in Biotechnology
Research, 97 YALE L.J. 117 (1987).
10. See infra part III, Other Legal Problems Associated with Patenting Living Organisms.
11. 35 U.S.C. § 101 (1982). General patent laws are contained in 35 U.S.C. §§ 1-376 (1982
& Supp. III 1985).
12. 447 U.S. 303 (1980).
13. In cases before Chakrabarty, biotechnology did not often produce patentable higher
life forms, so concern focused primarily on microorganisms.
14. 35 U.S.C. § 101 (1982). See, e.g., Funk Bros. Seed Co. v. Kalo Inoculant Co., 333 U.S.
127, 131 (1948) ("Discovery of the fact that certain strains of each species of these bacteria can
be mixed without harmful effect to the properties of either is a discovery of their qualities of
non-inhibition.").
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subject to patent protection, 15 the Supreme Court did not hold the
16
end product microorganisms patentable until Chakrabarty.
B.

Special Patent Acts

The United States Congress attempted to mesh patent law with
scientific advances in research involving living organisms.17 When Congress enacted the Plant Patent Act (PPA) in 1930, the United States
became the first nation to afford patent protection to new varieties
of asexually reproduced plants.18 Farmers, plant breeders, and government associations concerned with agricultural research and marketing
welcomed the PPA as an extension of general patent law.19 The PPA
rendered plants patentable subject matter.- It also modified several
21
general patent requirements, such as the enabling requirement.

See, e.g., Funk, 333 U.S. at 131:
The qualities of these bacteria, like the heat of the sun, electricity, or the qualities
of metal, are part of the storehouse of knowledge of all men. They are manifestations
of laws of nature, free to all men and reserved exclusively to none. He who
discovers a hitherto unknown phenomenon of nature has no claim to a monopoly
of it which the law recognizes.
Id. at 130. For a review of cases interpreting the "product of nature" rule, see Bloom, Designer
Genes and Patent Law: A Good Fit, 26 N.Y.L. SCH. L. REV. 1041, 1045-50 (1981). Those cases
are: Ex parte Latimer, 1889 Dec. Com. Pat. 123 (process of removing pine tree fiber is patentable,
fiber itself is not); Parke-Davis & Co. v. H.K. Mulford Co., 189 F. 95 (C.C.S.D.N.Y. 1911),
affd, 196 F. 496 (2d Cir. 1912) (patent for extracted, stable, concentrated adrenaline upheld
because for every practical purpose it was a new commercial, therapeutic thing); Merck & Co.
v. Olin Mathieson Chem. Corp., 253 F.2d 156 (4th Cir. 1958) (purified form of an existing natural
product is patentable only if the new product differs from the old in kind, not merely degree).
16. Bloom, supra note 15, at 1051; Eisenberg, supra note 9, at 208; Schlosser, Patenting
Biological Inventions, 12 U. TOL. L. REV. 925, 930 (1981). Product patents are more valuable
than process patents because product patents ensure greater protection for an inventor. Scientists
infringe on product patents if they try to market or to patent a patented product without regard
to whether they "discovered" the product using a new process.
17. "The development of patent law in the U.S. has followed technological advances."
Wershow, InternationalLegal Ramifications of Biotechnology, 1 FLA. INT'L L.J. 77, 94 (1986).
18. 35 U.S.C. §§ 161-164 (1982). "Whoever invents or discovers and asexually reproduces
any distinct and new variety of plant ... other than a tuber-propagated plant or a plant found
in an uncultivated state, may obtain a patent therefor . . . ." 35 U.S.C. § 161 (1982). The "tuber
exception" applies only to the Irish potato and the Jerusalem artichoke. These are the only two
asexually reproduced plants that are propagated by the part of the plant sold as food. Congress
may have excluded these plants to keep basic foods free from patent rights. Schlosser, supra
note 16, at 926-27.
19. Schlosser, supra note 16, at 926.
20. Id. at 927-28.
21. Id. "No plant patent shall be declared invalid for noncompliance with [35 U.S.C. § 112]
if the description is as complete as is reasonably possible." 35 U.S.C. § 162 (1982) [emphasis
15.

CAN CHAKRABARTY SURVIVE?

1988-1989]

These modifications were necessary to compensate for the unique problems associated with applying patent law to the scientific methods of
inventing living organisms. 2
In 1970, under the Plant Variety Protection Act (PVPA),- Congress extended patent-like protection to novel varieties of sexually
reproduced plants. This Act protects plant varieties that are distinct,
uniform, and stable.- The PVPA specifically excludes bacteria and
other microorganisms from protection.- The PPA and the PVPA provided the only means of patenting living organisms until 1980 when
the United States Supreme Court decided Chakrabarty.26
C.

Diamond v. Chakrabarty

In a five-to-four (5-4) decision, the United States Supreme Court,
in Chakrabarty, held that genetically engineered bacteria capable of
eating oil spills constituted patentable subject matter. 27 In determining
added]. Thus, the general patent enabling requirement is relaxed for plants. In addition, an
inventor need not supply a specimen as part of the examination process nor make the new plant
publicly available. Schlosser, supra note 16, at 927.
The PPA excludes sexually reproduced plants because in 1930, Congress did not believe that
the science of crop breeding was sufficiently advanced to guarantee stable and homogenous
sexually reproduced plants. Id. at 926.
22. Schlosser, supra note 16, at 926.
23. 7 U.S.C. §§ 2321-2583 (1982).
24. "The breeder of any novel variety of sexually reproduced plant (other than fungi,
bacteria, or first generation hybrids) who has so reproduced the variety, or his successor in
interest, shall be entitled to plant variety protection therefor .
7 U.S.C. § 2402(a)(1)-(3)
(1982).
25. 7 U.S.C. § 2402 (1982). Courts also interpret the PPA to exclude bacteria. Bloom,
supra note 15, at 1053. The PVPA originally excluded certain common vegetables from protection, but 1980 amendments removed the "vegetable exception" and lengthened the time of
protection to eighteen years. Environmentalists opposed the 1980 amendments, believing the
amendments would discourage natural genetic diversity. Schlosser, supra note 16, at 927.
26. Prior to 1980, the PTO granted patents for some living organisms, including yeast.
Yet, the courts did not interpret 35 U.S.C. § 101 to specifically include living organisms as
patentable subject matter until Chakrabarty. Bloom, supra note 15, at 1055.
27. Diamond v. Chakrabarty, 447 U.S. 303, 318 (1980). In 1972, Ananda Chakrabarty, a
microbiologist, filed both process and product patent applications for a human-made, genetically
altered bacteria capable of breaking down crude oil. Id. at 305. The patent examiner granted
the process patent, but denied the bacteria product claim because microorganisms were "products
of nature" and because living organisms were not patentable subject matter under 35 U.S.C.
§ 101. Id. at 306. Chakrabarty appealed to the Patent Office Board of Appeals which affirmed
on statutory grounds the patent examiner's decision. Id. The Court of Customs and Patent
Appeals reversed, relying on In re Bergy, 563 F.2d 1031, 1038 (1977), which held that for
purposes of patent law, the fact that a microorganism is alive is insignificant. Id. The Court of
Customs and Patent Appeals subsequently consolidated Chakrabarty and Bergy and obtained
certiorari. Id. at 306-07. Before the Supreme Court decided Chakrabarty, Bergy was dismissed
as moot. 444 U.S. 1028 (1980).

UNIVERSITY OF FLORIDA JOURNAL OF LAW & PUBLIC POLICY

[Vol. 2

that the bacteria were "manufactures" or "compositions of matter"
under the general patent laws, the Court relied on legislative intent
indicating that courts should broadly interpret and apply patent laws.2
The Court rejected the argument that Chakrabarty's bacteria were
products of nature since the bacteria displayed characteristics markedly different from existing bacteria - characteristics that gave them
new utility.29
The Chakrabarty Court found no merit in the argument that the
PPA and the PVPA evidenced congressional intent that manufactures
and compositions of matter under the general patent laws do not
include living organisms.- The Court reasoned that Congress enacted
the PPA to avoid challenges that plants were a product of nature and
to address the problem that new asexually reproduced plants were
not amenable to the written description requirement of the general
patent laws.31 The Court added that, when true-to-type sexual reproduction became possible, Congress similarly extended necessary patent-like protection in the 1970 PVPA. 32 According to the Court, Congress recognized that the relevant distinction, for purposes of product
patentability, was between products of nature, whether living or not,
and human-made inventions. 33
The Chakrabarty decision rests solely on an interpretation of 35
U.S.C. § 101. 34 Since Congress did not anticipate recent advances in

The Court defined "manufacture" in § 101 in accordance with its dictionary definition to
mean 'the production of articles for use from raw or prepared materials by giving to those
materials new forms, qualities, properties, or combinations, whether by hand-labor or by machinery."' 447 U.S. at 308 (citing American Fruit Growers, Inc. v. Brogdex, Co., 283 U.S. 1, 11
(1931)). The Court defined "composition of matter" to mean "all compositions of two or more
substances and . . . all composite articles, whether they be the results of chemical union, or of
mechanical mixture, or whether they be gases, fluids, powders or solids." Id. (quoting Shell
Dev. Co. v. Watson, 149 F. Supp. 279, 280 (D.C. 1957) (citing 1 A. DELLER, WALKER ON
PATENTS 14, at 55 (1st ed. 1937)).
28. 447 U.S. at 308. The Court noted that the Patent Act embodied author Thomas Jefferson's philosophy that "ingenuity should receive a liberal encouragement." Id.
29. Chakrabarty's "claim is not to a hitherto unknown natural phenomenon, but to a nonnaturally occurring manufacture or composition of matter - a product of human ingenuity
'having a distinctive name, character [and] use."' Id. at 309-10 (citing Hartranft v. Wiegmann,
121 U.S. 609, 615 (1887)).
30. 447 U.S. at 311.
31. Id. at 311-12.
32. Id. at 313. The Court observed that when Congress passed the PPA in 1930, new
sexually reproducing plant varieties could not be reproduced true-to-type through seedlings at
that time. Id.
33. Id.
34. Id. at 307.
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scientific technology when it enacted the PPA and the PVPA, the
Court did not accept the notion that living organisms are not patentable
absent specific legislation. 3 According to the Court, "Congress employed broad general language in drafting section 101 precisely because
such inventions are unforeseeable. '36 The Court explained that Congress intended that "anything under the sun made by man" qualify
37
for patent protection.
Because the case required only statutory interpretation, the Court
specifically declined to examine the potential hazards, moral considerations, or philosophical ramifications of patenting living organisms.3
Instead, the Court deferred to Congress to assess the risks and ben39
efits of biotechnology.
The dissent in Chakrabartyargued that if man-made, non-naturally
occurring, asexually and sexually reproduced plants were patentable
under section 101 as "manufactures" or "compositions of matter," then
Congress enacted the PPA and the PVPA unnecessarily.49 The dissent
pointed to the exclusion of bacteria and other microorganisms under
the PPA as additional evidence of congressional intent to create a
very narrow exception to the rule that living organisms are not patentable.4 1 Like the majority, the dissent noted that Congress should act
to broaden or narrow the reach of patent law especially when "the
composition sought to be patented uniquely implicates matters of public
concern. '42 Because the Court in upholding the bacteria patent in
Chakrabarty used broad language which supported the patentability
of man-made microorganisms, critics have argued that the decision
opens the door for patenting any man-made living organism.- 3

35. Id. at 314-15.
36. Id. at 316.
37. Id. at 309 (citing S. REP. No. 1979, 82d Cong., 2d Sess. 5 (1952); H.R. REP. No. 1923,
82d Cong., 2d Sess. 6 (1952)).
38. Id. at 318-19.
39. Id. at 318.
40. Id. at 320.
41. Id. at 319, 321. See supra note 25.
r42. 447 U.S. at 322. See infra note 53 and accompanying text (bills proposed in response
to Chakrabartyand PTO decisions). In criticizing the Chakrabartydecision, Bloom noted that
[blecause genetic engineering is a new field which impacts areas other than patents,
no patents should be granted until Congress legislatively defines a policy. Genetically engineered microorganisms can potentially cause great harm and there should
be no encouragement of further research and development until Congress has
considered the issues involved.
Bloom, supra note 15, at 1055-56.
43. Ananda Chakrabarty transferred the plasmids of bacteria to create their oil decomposing
property. Recombinant DNA techniques were not involved. The Chakrabarty court failed to
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After Chakrabarty

After Chakrabarty,the PTO adopted a policy of judging the patentability of man-made living organisms, other than microorganisms, on
a case-by-case basis. 44 In Ex parte Hibberd,45 the examiner concluded
that maize plant technologies are patentable under section 101 despite
the availability of other plant-specific acts.4 6 The examiner rejected
the theory that the plant acts are the exclusive means of protecting
plant life; unless irreconcilable conflict exists, both section 101 and
the plant acts must be given full effect. 47 Thus, the PTO expanded
Chakrabartyto effectively eliminate the need for plant-specific patenting acts. 48 The PTO's action supports the Chakrabartydissent's view
that the PPA and the PVPA are unnecessary if plants are patentable
subject matter under the general patent laws.
The examiner in Ex parte Allen49 upheld the Hibberd examiner's
expansive reading of Chakrabarty. In Allen, the examiner determined
that non-naturally occurring polyploid oysters are patentable subject
matter under general patent law. - Four days after the Allen decision,
the Patent Commissioner announced the PTO's intention to issue patents for man-made, non-human multicellular living organisms. 51 Eight
months later, the PTO issued the "Harvard mouse" patent.52
The PTO's willingness to extend Chakrabartyto current biotechnology creations has spawned a number of congressional bills.H Only one
consider the ramifications of other genetic engineering techniques by focusing solely on the
question of statutory interpretation. 447 U.S. at 305-06. Schlosser, supra note 16, at 952.
44. Schlosser, supra note 16, at 931. In effect, the PTO decided Chakrabarty could be
applied to living organisms engineered using other techniques absent congressional direction to
the contrary. Id. at 952. In 1981, soon after the Chakrabartydecision, at least one commentator
supported the patentability of living organisms but did not see the need for defining an upper
limit of complexity for patenting living organisms. The commentator considered genetic engineering too immature to warrant such a limit. The author predicted, however, that new technology
would lead to re-evaluation of existing patent law. Sparrow, An International Comparative
Analysis of the Patentability of Recombinant DNA-Derived Organisms, 12 U. TOL. L. REV.
945, 957 (1981).
45. 227 U.S.P.Q. (BNA) 443 (1985).
46. Id. at 444.
47. Id. at 446.
48. The patent examiner affirmed the availability of both the plant-specific acts and 35
U.S.C. § 101 for plant patent protection. Id.
49. 2 U.S.P.Q.2d 1425 (1987). The patent, however, was denied on "obviousness" grounds.
Id. at 1427.
50. Id. at 1426-27.
51. 36 PAT. TRADEMARK & COPYRIGHT J. (BNA) 271 (1988).
52. See supra notes 1-4 and accompanying text.
53. 36 PAT. TRADEMARK & COPYRIGHT J. (BNA) 271, 346 (1988). The most prominent
bills are: S. 2111, 100th Cong., 2d Sess. (1988) (The bill would add a section to 35 U.S.C.,
containing the following language:
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bill, however, has made significant progress out of committee.4 Meanwhile, researchers continue to produce useful genetically engineered
living organisms like the "Stanford mouse."55 However, the production
of these types of organisms intensifies the controversy surrounding

Vertebrate or invertebrate animals, modified, altered, or in any way changed
through engineering technology, including genetic engineering, shall not be considered matter within the confines of patentability and shall not be patentable within
the meaning of section 101 or section 102 or any other provision of this title. No
such patent shall be granted and any patent previously granted for any such animals
are hereby revoked.
(Senator Hatfield sponsored the indefinite moratorium bill which is currently pending before
the Senate Judiciary Committee. An aide to Senator Hatfield expressed the opinion that the
bill would likely "die on the vine.")); H.R. 3119, 100th Cong. 1st Sess. (1987) (Representative
Rose sponsored this bill. It was defeated by the judiciary subcommittee in July 1988. The bill
would have provided a two year moratorium on animal patenting which would have terminated
upon Congress' establishing regulatory review. The bill recited congressional findings that
(1) the patenting of genetically engineered invertebrate and vertebrate animals,
including animals engineered with human genetic traits, raises profound economic,
environmental, and ethical questions which Congress has not had the opportunity
to fully address; (2) untimely action on this issue could unnecessarily expose patent
holders to the revocation of their patents and expose the Government to financial
liability for their restitution; (3) vertebrate and invertebrate animals have never
been patentable under the patent laws of the United States; (4) such monumental
decisions about the fate of animal life should not be left solely to the Patent and
Trademark Office);
H.R. 4970, 100th Cong., 2d Sess. (1988) (Representative Kastenmeier introduced the "Transgenic
Animal Patent Reform Act" which would permit animal patenting to continue but would allow
researchers and farmers to breed and sell patented animals without infringement under some
circumstances. H.R. 4970 also contains a provision excluding human beings as patentable subject
matter. This bill passed in the House of Representatives on September 13, 1988); H.R. 4971,
100th Cong., 2d Sess. (1988) (Representative Kastenmeier also introduced the "Transgenic Animal Regulatory Reform Act" which establishes a Biotechnology Science Coordinating Committee
(BSCC). The BSCC has five functions:
(1) to serve as a coordinating forum for addressing scientific problems, sharing
information, and developing consensus with respect to methods for evaluating potential risks to human health and the environment which are or may be caused by
genetically engineered animals, (2) to promote uniformity in the development of
review procedures and assessments for evaluating such risks, (3) to facilitate continuing cooperation among Federal agencies on emerging scientific issues related
to such animals and such risks, (4) to identify gaps in scientific knowledge with
respect to such animals and such risks, and (5) to develop guidelines to govern
good laboratory and good manufacturing practices in the biotechnology sciences.
The BSCC would also issue permits for using genetically-altered animals in agricultural activities.
Congress has not taken action on this bill.).
54. H.R. 4970, 100th Cong., 2d Sess. (1988).
55. Scientists at Stanford University transplanted elements of the human immune system
into mice. This technique will have important uses in the study of AIDS and leukemia and in
the testing of treatments and vaccines. N.Y. Times, Sept. 15, 1988, at Al, A13.
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biotechnology.56 The biotechnology-patent controversy suggests that
Congress should accept the Chakrabartychallenge to evaluate existing
patent law in light of the issues and problems raised by living organism
patents.
III.

OTHER LEGAL PROBLEMS ASSOCIATED WITH
PATENTING LIVING ORGANISMS

The plea for congressional action by both the majority and the
dissent in Chakrabarty57 indicates that advances in biotechnology present complex legal problems. First, certain provisions of the general
patent laws are difficult to apply to biotechnology products. Second,
the process of patenting living organisms presents unique regulatory
challenges.
A.

Other Patenting Problems

Given that living organisms are patentable subject matter, a patent
applicant must establish that the invention is novel,5 useful, 59 and not
obvious 6Obefore the PTO will grant a patent.6 1 In the patent application, the applicant must describe the claimed invention in writing,
explain the invention in sufficient detail to "enable" those skilled in
the art to "make and use" the invention, and disclose the "best mode"
of carrying out the invention.2 By fulfilling these requirements, the

56. Boffey, Use of Fetal Tissue as Cure Debated, N.Y. Times, Sept. 15, 1988, at A31.
Scientists urge the use of human fetal tissue in treating incurable diseases like Parkinson's and
Alzheimer's. One scientist has indicated that it would be unethical not to try the procedures on
patients because the animal experiments have been "so promising." Id. Opponents of the use
of fetal tissue, including former President Ronald Reagan, would bar such use, arguing that it
could induce women to have abortions and because the newborn and the unborn would not
benefit directly from experimentation. Id.
57. 447 U.S. 303, 317-18, 322 (1980).
58. 35 U.S.C. §§ 101, 102 (1982).
59. Id.
60. A patent applicant must satisfy the following:
A patent may not be obtained . . . if the differences between the subject matter
sought to be patented and the prior art are such that the subject matter as a
whole would have been obvious at the time the invention was made to a person
having ordinary skill in the art and to which said subject matter pertains.
35 U.S.C. § 103 (1982).
61. 35 U.S.C. §§ 154, 271(a) (1982).
62. The act requires that
[t]he specification shall contain a written description of the invention, and of the
manner and process of making and using it, in such full, clear, concise, and exact
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patent applicant ensures that the public will inherit the full benefit of
the invention and that the PTO will have sufficient information to
approve the patent 3
1. Timing
Due to the nature of biotechnology research inventions, inventors
of patentable living organisms face unique problems in adhering to
patent statutory requirements. To beat out competitors and to secure
an investment return on a biotechnology product, a researcher should
apply for a patent when early research shows promise.- However, at
the first signs of positive research results, the researcher may have
trouble describing a claimed invention in sufficient detail to "enable"
those skilled in the art to "make and use" the invention.
Patent application at early stages of research is also important
because the patenting process typically takes approximately five to
six years.- The rapid pace of biotechnology research often prevents
the inventor from reaping the maximum advantages of patent protection. Biotechnology researchers must, therefore, find other ways to
67
protect their inventions during the research process.
2. Scope
The inventor may have trouble defining the scope of the patent
when applying for patent protection at any stage of research. The
"enabling" description of the claimed invention determines the scope
of the patent,6 9 and the patent's scope defines its boundaries of protec-

terms as to enable any person skilled in the art to which it pertains, or with which
it is most nearly connected, to make and use the same, and shall set forth the
best mode contemplated by the inventor of carrying out his invention.
35 U.S.C. § 112.
63. See Eisenberg, supra note 9, at 207 (discussing patent protection and the scientific
reward system).
64. An example of the need to beat out the competition is provided by the recent dispute
over property rights and scientific credit for the discovery of a test to detect the presence of
antibodies to the AIDS virus. Eisenberg, supra note 9, at 226-29.
65. 35 U.S.C. § 112 (1982).
66. Naj, Clouds Gathering Over the Biotech Industry, Wall St. J., Jan. 30, 1989, at B1.
67. Other means of protecting inventions from infringement, such as trade secrecy, are
generally not considered as effective or desirable as patent protection. See infra note 111.
68. A patent application describes the claimed invention. Patent protection does not extend
beyond what the patent applicant has claimed as an invention. "The specification shall conclude
with one or more claims particularly pointing out and distinctly claiming the subject matter
which the applicant regards as his invention." 35 U.S.C. § 112 (1982).
69.

Id.
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tion in an infringement action. Ex parte Jackson7" suggests that the
scope of a patent for a living organism is limited to the organisms the
inventor deposits. 7' The patent's scope, however, does not extend to
other organisms of the same species if the inventor has not enabled
other scientists to create the other species members using the original
patent application.7- If the applicant subsequently invents new organisms of the same species, the new organisms will not qualify for
protection under the original patent. 3
Since biotechnology research advances so rapidly, the scope of a
patent may quickly become outdated. 74 Competitors may achieve new
results that fall outside the scope of the patent but will effectively
invade the patent's protected market. 7- In addition, courts may narrowly interpret existing patents to aid other researchers in developing
new biotechnology products.
3.

Deposit

The deposit requirement provides another obstacle for a biotechnology patent applicant.76 The PTO fashioned the deposit requirement
because researchers who used living organisms encountered difficulty
in "enabling" those skilled in the art "to make or use" their invention
with only a written specification.- However, rapid advances in

70. 217 U.S.P.Q. (BNA) 804 (P.T.O. Bd. App. 1982).
71. The deposit requirement may narrow the scope of the patent even if the situation where
the written specification alone would "enable" one skilled in the art to reproduce deposited
organisms. However, the scope of a patent will extend to cover mutations of deposited organisms.
Id. at 806. Jackson suggests that an inventor will want to make a large number of deposits to
expand the scope of the patent. Note, supra note 7, at 600-03. The deposit requirement is
discussed in more detail in subsection 3 of this section.
72. 217 U.S.P.Q. at 807-08.
73. Id.
74. See Eisenberg, supra note 9, at 215.
75. See infra subsection 4 of this section.
76. A patent applicant must deposit the claimed invention prior to filing an application.
Manual of Patent Examining Procedure 608.01(c) (5th ed. 1983, rev. 1985). Cf. In re Lundak,
773 F.2d 1216 (Fed. Cir. 1985), where the court rejected the PTO's deposit before the filing
requirement. The PTO subsequently proposed a rule to update its deposit requirement in light
of Lundak. Eisenberg, supra note 9, at 211 n.175.
The PVPA also adheres to a deposit requirement. 7 U.S.C. § 2422 (1982).
77. The PTO first required a deposit because inventors were using new and rare organisms.
Now the PTO requires a deposit because inventors create new organisms which other scientists
often cannot replicate solely by using a written specification. Note, supra note 7, at 596.
In In re Argoudelis, 434 F.2d 1390 (C.C.P.A. 1970), the court approved the use of a deposit
to "enable" others to replicate an invention, but held that 35 U.S.C. § 112 did not require public
access to the deposit before the PTO issues a patent. Id. at n.37.
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biotechnology and widespread dissemination of biotechnology information recently have enabled many scientists to replicate patented microorganisms using only the written specification, thus rendering a deposit
unnecessary. 7 8
Costly deposits increase the expense of biotechnology patents, 79
especially if many deposits are required to ensure that the patent has
a broad scope.- The lack of a clear standard specifying the required
deposit also creates confusion regarding the deposit requirement.81 In
addition, the PTO's failure to regulate depositories allows for public
disclosure of an invention before a patent is issued. s2
4.

Infringement

The race among scientists to discover and patent biotechnology
inventions has spawned an increasing amount of patent litigation.Litigated issues include not only the breadth of a patent's scope but
also whether later advances require narrowing the scope of an earlier
patent, and whether the patentee has complied with deposit requirements. 84 Further, the obviousness and novelty of a patented invention
may be called into question by competitors who seek to challenge
existing patents, or who seek to protect or market their own inventions.- Since judges have difficulty in assessing the validity of patents
based on complex and ever-changing technology,6 infringement actions
become battles of experts and exercises in hindsight.
In Lear, Inc. v. Adkins,87 the Supreme Court held that a licensee
of a patented invention could challenge the validity of the patent under
which the licensee was working.- The Court reasoned that federal
interest in free access to inventions required it to overrule the state
doctrine of licensee estoppel that prohibited a licensee from challenging
the validity of the patent. Licensee estoppel allows a patent holder,
78. Note, supra note 7, at 595.
79. Id.
80. See supra notes 70-73 and accompanying text.
81. Note, supra note 7, at 595.
82. Id. at 604.
83. See Adamo, Adjudicating Infringement in Biotechnology Patent Cases - Out with the
Old Rules, In with the New? (Feb. 18-19, 1988) (paper presented at the John Marshall Law

School Center for Intellectual Property Law, 32d Annual Conference on More Developments in
Intellectual Property Law).
84. Id.
85. Id.

86. Id.
87.
88.
89.

395 U.S. 653 (1969).
Id. at 654.
Id. at 654, 661-62.
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pursuant to a contractual arrangement with the licensee, to secure a
stream of income from an invention until the patent expires.9° The
Lear decision increases the possibility of litigation over patent validity
because it increases the number of people who have a stake in invalidating the patent.
Moreover, a host of patent treaties extend patent protection to
many countries.91 The varying requirements of these treaties create
uncertainty about the scope of patent protection and provide new
bases for litigation.92
The legal problems associated with patenting living organisms are
not confined to patent law. A comprehensive system of federal regulation is necessary to guide scientific research procedures inside the
laboratory and to oversee application of biotechnology products outside
the laboratory. Further, federal regulation is needed to assess the
risks of biotechnology and to prevent biotechnology disasters.
B.

Regulation

The federal government fails to uniformly regulate biotechnology
inventions. The hodgepodge of existing statutes provides only limited
protection.- The lack of a uniform system of regulation creates uncertainty that may stifle commercial developments in biotechnology. The
regulatory void may also inhibit data collection, thereby preventing
the government from adequately assessing the potential risks of
biotechnology inventions.- Recombinant DNA technology and other
genetic engineering techniques have spawned concerns about their

90. Inventors ensure protection of their investments by spreading part of the risk of invalidation or infringement to a licensee by contractual agreement. Licensees typically agree to pay
royalties for a specific amount of time (perhaps longer than 17 years) and not to contest the
patent's validity. Inventors thus receive a certain return on their investment, and a licensee
may bargain for a "price" that reflects the likelihood that the patent will be infringed or invalidated. Dreyfuss, Dethroning Lear: Licensee Estoppel and the Incentive to Innovate, 72 VA. L.
REV. 677, 679-81 (1986).
91. See Wershow, supra note 17, at 99-107.
92. Id.
93. For pending proposed federal regulation, H.R. 4971, see supra note 53. Several law
review articles and notes discuss existing means of federal regulation. See e.g., McGarity &
Bayer, Federal Regulation of Emerging Genetic Technologies, 36 VAND. L. REV. 461, 500-37
(1983); Wershow, supra note 17, at 82-94; Note, The E.P.A. and Biotechnology Regulation:
Coping with Scientific Uncertainty, 95 YALE L.J. 553 (1986) (authored by Ruth E. Harlow)
[hereinafter Note, E.P.A.]; Note, The Rutabagathat Ate Pittsburgh:Regulation of FreeRelease
Biotechnology, 72 VA. L. REV. 1529, 1535-49 (1986) (authored by Michael P. Vandenbergh)
[hereinafter Note, Rutabaga].
94. Note, Rutabaga, supra note 93, at 1530.
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effects on human health and the environment. 95 In addition, many
object to biotechnology researchers' use and manipulation of human
and animal genes. 96
The National Institute of Health (NIH) has established guidelines
for conducting biotechnology research. 97 Initially, guidelines focused
on preventing accidental escape of recombinant DNA products. 98 The
NIH later relaxed the guidelines when the public recognized the potential benefits and commercial profits biotechnology products offer. 9Private research organizations voluntarily follow the NIH guidelines.
Loss of federal funding is the only penalty for failure to abide by the
guidelines.10°
Some federal agencies attempt to regulate the release of biotechnology products under existing statutes. However, the inability of agencies to oversee all stages of the research process, and their often
questionable jurisdiction over biotechnology research and products,
indicates that a comprehensive regulatory system is needed.10 1 In addition, rapid advancement in biotechnology results in a lack of expertise required to properly evaluate risks of releasing certain living
organisms. 102
Congress proposed and considered several bills regarding the regulation of biotechnology. 10 3 Without legislative enactments, however,
the bills fail to establish firm guidance. The reasons for sluggish congressional response to biotechnology issues include a lack of public
demand for legislation and a low probability that biotechnology inventions will cause disastrous results.""
Continued advances in biotechnology will likely bring increased use
of human genetic material, manipulation of higher life forms, and promise of commercial application.- ° Accordingly, a uniform method of regulation is crucial to address risks that are likely to accompany these
biotechnology advances.
95. In the environment, out of the control of the laboratory, microorganisms may wipe out
existing microorganisms or may combine with them and mutate. Id. at 1534.
96. Id. at 1535-1536 n.38.
97. NIH responded as a result of increasing public concern about recombinant DNA
technologies in the mid-1970s. NIH responded only after members of Congress introduced twelve
bills with no emerging legislation. Note, Rutabaga, supra note 93, at 1535-37.
98. Id. at 1537.
99. Id.
100. Wershow, supra note 17, at 82-83.
101. See articles cited supra at note 93.
102. Note, E.P.A., supra note 93, at 558.
103. See supra notes 53 & 97.
104. McGarity & Bayer, supra note 93, at 538.
105. See infra part IV, section A.
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PUBLIC POLICY CONSIDERATIONS

In addition to sparking a reassessment of Chakrabarty and the
legal challenges associated with patenting living organisms, the PTO's
decision to grant patent protection to the "Harvard mouse" demands
evaluation of several public policy issues.
A.

Biotechnology Benefits

The "Harvard mouse" exemplifies the potential benefits biotechnology can provide for cancer research. '- Biotechnology has also advanced
research for curing Parkinson's disease and AIDS. 107 In addition, scientists have discovered methods for producing human growth hormone
and insulin using recombinant DNA techniques.10s Chakrabarty's oil
ingesting bacteria have even provided a biotechnology method of cleaning up damaging oil spills at sea. 10 9
The United States remains at the forefront of biotechnology research and development. Some commentators question the United
State's ability to maintain its leadership role because of the legal
problems involved with protecting biotechnology inventions and the
uncertain biotechnology climate.11° In light of the many benefits
biotechnology inventions may provide, the federal government should
provide the protections necessary to ensure that the American consumer reaps the rewards that biotechnology offers.B.

Investment

While modern biotechnology raises ethical and moral issues, its
potential benefits have encouraged a tremendous amount of both public
and private investment. 112 When Chakrabartyensured the patentability of living organisms, investment by both large and small biotechnology companies increased considerably.1 13 Although the United States

106. See supra notes 1-4 and accompanying text.
107. See supra notes 55 & 56 and accompanying text.
108. Note, Rutabaga, supra note 93, at 1532.
109. See supra note 27 and accompanying text.
110. Note, Rutabaga, supra note 93, at 1530.
111. Patent law provides the best means to provide stability and predictability in biotechnology product research and development. State law of trade secrecy, contractual arrangements,
and copyright law are all inadequate to protect both investment and ownership while allowing
the public to benefit from the free flow of scientific knowledge. See Pollack, The New High-Tech
Battleground, N.Y. Times, July 3, 1988, at B1, B8.
112. See Eisenberg, supra note 9, at 181; OTA: INVESTMENT, supra note 7, at 131-247.
113. A boom in biotechnology company formation occurred between 1980 and 1984. OTA:
INVESTMENTS, supra note 7, at 9. Small biotechnology investment firms may be at a disadvan-
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should encourage investment in biotechnology, current conditions demand that the government address ethical and moral concerns.
C.

Ethical Concerns

Gene splicing, use of fetal matter, human/animal genetic material
exchange, and other biotechology research methods have caused a
resurgence of ethical and moral objections to biotechnology research. 114
When biotechnology involves genetic manipulation of mammals, the
federal government must respond to challenges that scientists violate
species integrity."15 Patent protection may afford a means to protect
the required investment in biotechnology and to consider the risks
inherent in biotechnology research and product development.
V.

CONCLUSION AND PROPOSALS

Although the "Harvard mouse" patent demonstrates the potential
societal benefits of biotechnology, 116 the patent also reveals how
biotechnology has advanced well beyond the general patent laws' ability to sufficiently protect the public and the patentee.' 17 Since patent
protection is granted in exchange for dissemination of knowledge to
the public, patent law provides a useful vehicle to address the regula-8
tion and protection concerns of both the public and the patentee."1
Other methods of protection for biotechnology inventions, like trade
secrecy,"19 would allow an inventor to recoup research and development
investments. These methods, however, would hide information about
the investment from the government and the public, thereby frustrating regulatory efforts and further scientific development.' 2°

tage in their inability to pay for numerous deposits or to assume risks of uncertain investment
return. Dreyfuss, supra note 90, at 680.
114.

See

OFFICE OF TECHNOLOGY ASSESSMENT, U.S. CONG.,

07A-BA-337, NEW DEVEL-

OPMENTS IN BIOTECHNOLOGY: OWNERSHIP OF HUMAN TISSUES AND CELLS -

SPECIAL

REPORT 129-44 (1987).

115. The government controls some types of information, like military information, to ensure
that government public policies are not circumvented. There may be valid reasons to keep some
types of knowledge secret. DuVal, The Occasions of Secre, ".47 U. PITT. L. REV. 579, 606,
670-71 (1986).
116. See supra notes 106-09 and accompanying text.
117. See supra part III.
118. Eisenberg, supra note 9, at 206.
119. See Note, All the King's Horses - IrreparableHarm in Trade Secret Litigation, 52
FORDHAM L. REV. 804 (1984).
120. Eisenberg, supra note 9, at 193-95.
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One effective method of addressing many of the concerns posed in
this article is to provide a separate biotechnology patenting statute.
First, Congress should draft legislation, within the Chakrabarty
parameters, specifying that living organisms are patentable. 121 Second,
Congress should recognize the importance and complexity of the controversy surrounding biotechnology by passing a patent act for
biotechnology products. Finally, Congress should create a special patent examining committee, composed of experts in biotechnology, as
a separate branch of the PTO. The committee would advise Congress
in drafting a biotechnology patent statute and would issue patents.
Biotechnology experts would be in a position to recommend new
timing requirements for patent applicants122 and to aid in properly
defining the scope of a patent.1 2 An examining committee composed
of experts could also review the deposit requirement to provide a
more definite deposit standard.124 Further, the committee could determine whether to waive the deposit for certain technologies. By tailoring a statute to specifically address the unique problems of biotechnology, and by establishing an expert examining committee to apply the
statute, the federal government would infuse predictability and uniformity into the patenting process. Predictable and uniform patent laws
will decrease the amount of patent litigation and increase public confidence in the patenting process.
Another useful provision of a biotechnology patenting statute would
deny patent protection to any patent applicant who did not follow
specified research guidelines.125 Though the task of this article is not
to revamp the biotechnology regulatory structure, any regulation will
be strengthened by tying it to the patent law. Requiring a potential
patent applicant to follow federal research guidelines would encourage
scientists to adhere to those guidelines to obtain valuable patent protection for their inventions.2 6
Regulatory and protective goals would be enhanced by inclusion
of a method of risk/benefit assessment for the examining committee
to use during the patent examination process.1 27 A balanced pre-patent
risk assessment could be accomplished by the biotechnology patent
examining committee. Composed not only of biotechnology scientists

121.
122.
123.
124.
125.
126.
127.

See
See
See
See
See
Id.
See

supra notes
supra notes
supra notes
supra notes
supra notes

106-09 and accompanying text.
64-68 and accompanying text.
68-82 and accompanying text.
76-82 and accompanying text.
97-100 and accompanying text.

Note, E.P.A., supra note 93, at 557.
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and business persons, but also of persons charged with posing ethical
considerations, 12 the committee would ensure that the government
has considered relevant information before issuing a patent.
The many problems and concerns associated with patenting living
organisms demonstrate the need for legal reform. Since patent protection is important to protect investments in biotechnology, patent law
is a logical place to address reform efforts. 1 9 Patent law reform may
not be useful without accompanying regulatory reform. As the
biotechnology revolution moves forward, current inadequacies in the
law are likely to become even more apparent. The challenge for Congress is to mesh the law with biotechnology trends and to anticipate
future advances before those advances overwhelm both law and
society.

128.
129.

Id. at 560-63.
See Eisenberg, supra note 9, at 230-31.

